09 November 2023
EMA/453895/2023
EMEA/H/C/005205

Public statement

Zynrelef (bupivacaine / meloxicam)

Withdrawal of the marketing authorisation in the European Union

On 5 October 2023, the European Commission withdrew the marketing authorisation for Zynrelef (bupivacaine / meloxicam) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Heron Therapeutics, B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Zynrelef was granted marketing authorisation in the EU on 24 September 2020 for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.

The European Public Assessment Report (EPAR) for Zynrelef will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union